Drug delivery strategies for therapeutic angiogenesis and antiangiogenesis

Expert Opinion on Drug Delivery

Volumn 8, Issue 4, 2011, Pages 485-504

  Bhise, Nupura S ^a   Shmueli, Ron B ^a   Sunshine, Joel C ^a   Tzeng, Stephany Y ^a   Green, Jordan J ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Age related macular degeneration; angiogenesis; antiangiogenesis; biomaterials; cancer; drug delivery; ischemia; nanoparticle

Indexed keywords

AFLIBERCEPT; ALACIZUMAB PEGOL; ANECORTAVE; BECAPLERMIN; BEVACIZUMAB; CARMUSTINE; CETUXIMAB; CILENGITIDE; DOXORUBICIN; ERLOTINIB; EVEROLIMUS; GEFITINIB; HYPOXIA INDUCIBLE FACTOR 1ALPHA; NANOPARTICLE; OXALIPLATIN; PACLITAXEL; PANITUMUMAB; PEGAPTANIB; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PIGMENT EPITHELIUM DERIVED FACTOR; RANIBIZUMAB; SORAFENIB; STEROID; SUNITINIB; TARVECA; TEMSIROLIMUS; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN 165;

ADVANCED CANCER; ANGINA PECTORIS; ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SIZE; CARDIOVASCULAR DISEASE; CELL THERAPY; COLORECTAL CANCER; DIABETIC FOOT; DISEASE COURSE; DRUG CONJUGATION; DRUG COST; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; ENDOTHELIUM CELL; EPITHELIUM CELL; EX VIVO GENE TRANSFER; EXUDATIVE MACULAR DEGENERATION; GENE OVEREXPRESSION; GLIOBLASTOMA; HEAD CANCER; HEART MUSCLE ISCHEMIA; HUMAN; KIDNEY CARCINOMA; LIMB ISCHEMIA; LIPOSOMAL DELIVERY; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MELANOMA; METASTASIS; MONONUCLEAR CELL; MYOBLAST; NECK CANCER; NONHUMAN; PANCREAS CANCER; PERIPHERAL VASCULAR DISEASE; PROSTATE CANCER; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; TARGET CELL; TISSUE ENGINEERING; TREATMENT DURATION; TUMOR SUPPRESSOR GENE; TUMOR VASCULARIZATION;

ANGIOGENESIS INDUCING AGENTS; ANGIOGENESIS INHIBITORS; ANIMALS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; ISCHEMIA; MACULAR DEGENERATION; NANOPARTICLES; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC;

EID: 79952942752     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425247.2011.558082     Document Type: Review

References (202)

1. Phelps EA, Garcia AJ. Update on therapeutic vascularization strategies. Regen Med 2009;4(1):65-80. This article is a good review on current advances in vascularization strategies used in the fields of tissue engineering and regenerative medicine.
2. Eichmann A, Pardanaud L, Yuan L, et al. Vasculogenesis and the search for the hemangioblast. J Hematotherapy Stem Cell Res 2002;11(2):207-14 (Pubitemid 34309516)
3. Risau W. Mechanisms of angiogenesis. Nature 1997;386(6626):671-4 (Pubitemid 27193480)
4. Glotzbach JP, Levi B, Wong VW, et al. The basic science of vascular biology: Implications for the practicing surgeon. Plast Reconstr Surg 2010;126(5):1528-38
5. Folkman J. Angiogenesis in psoriasis: Therapeutic implications. J Invest Dermatol 1972;59:40-3
6. Moulton KS. Angiogenesis in atherosclerosis: Gathering evidence beyond speculation. Curr Opin Lipidol 2006;17:548-55 (Pubitemid 44372686)
7. Moulton KS. Inhibition of plaque neovascularization reduces macrophage accumulation and progression of advanced atherosclerosis. Proc Natl Acad Sci USA 2003;100:4736-41 (Pubitemid 36457799)
8. Paleolog EM. Angiogenesis in rheumatoid arthritis. Arthritis Res 2002;4(Suppl 3):S81-90
9. Brown RA, Weiss JB, Tomlinson IW, et al. Angiogenic factor from synovial fluid resembling that from tumours. Lancet 1980;1(8170):682-5 (Pubitemid 10131683)
10. Martin A, Komada MR, Sane DC. Abnormal angiogenesis in diabetes mellitus. Med Res Rev 2003;23(2):117-45 (Pubitemid 36241095)
11. Folkman J. Tumor angiogenesis: Therapeutic implications. N Engl J Med 1971;285:1182-6
12. Miller JW. Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am J Pathol 1994;145:574-84 (Pubitemid 24285965)
13. Folkman J. Angiogenesis: An organizing principle for drug discovery? Nat Rev Drug Discov 2007;6(4):273-86 (Pubitemid 46505878)
14. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003;3(6):401-10 (Pubitemid 37328844)
15. Abdollahi A, Folkman J. Evading tumor evasion: Current concepts and perspectives of anti-angiogenic cancer therapy. Drug Resist Updat 2010;13(1-2):16-28
16. Ferrara N. Vascular endothelial growth factor: Basic science and clinical progress. Endocr Rev 2004;25(4):581-611 (Pubitemid 39099316)
17. Cross MJ, Claesson-Welsh L. FGF and VEGF function in angiogenesis: Signalling pathways, biological responses and therapeutic inhibition. Trends Pharmacol Sci 2001;22(4):201-7 (Pubitemid 32244307)
18. Giles FJ. The vascular endothelial growth factor (VEGF) signaling pathway: A therapeutic target in patients with hematologic malignancies. Oncologist 2001;6(Suppl 5):32-9 (Pubitemid 33054875)
19. Hall H. Modified fibrin hydrogel matrices: Both, 3D-scaffolds and local and controlled release systems to stimulate angiogenesis. Curr Pharm Des 2007;13(35):3597-607 (Pubitemid 350238931)
20. Weinberg RA. The Biology of Cancer, 270 Madison Avenue, Garland Science, Taylor and Francis Group LLC, New York, NY; 2007
21. Browder T, Butterfield CE, Kraling BM, et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000;60(7):1878-86 (Pubitemid 30207647)
22. Wu HC, Chang DK. Peptide-mediated liposomal drug delivery system targeting tumor blood vessels in anticancer therapy. J Oncol 2010;2010:723798
23. Jain RK. Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science 2005;307(5706):58-62 (Pubitemid 40093472)
24. Ng QS, Goh V, Milner J, et al. Acute tumor vascular effects following fractionated radiotherapy in human lung cancer: In vivo whole tumor assessment using volumetric perfusion computed tomography. Int J Radiat Oncol Biol Phys 2007;67(2):417-24 (Pubitemid 46108337)
25. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350(23):2335-42 (Pubitemid 38702844)
26. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355(14):1419-31 (Pubitemid 44511557)
27. Gragoudas ES, Adamis AP, Cunningham ET Jr, et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351(27):2805-16 (Pubitemid 40051904)
28. Dixon JA, Oliver SC, Olson JL, et al. VEGF Trap-Eye for the treatment of neovascular age-related macular degeneration. Expert Opin Investig Drugs 2009;18(10):1573-80
29. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354(6):567-78 (Pubitemid 43209104)
30. Van Cutsem E, Kohne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360(14):1408-17
31. Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007;25(13):1658-64 (Pubitemid 46797944)
32. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet 2010;376(9742):687-97
33. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344(11):783-92 (Pubitemid 32222155)
34. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361(10):947-57
35. Cappuzzo F, Ciuleanu T, Stelmakh L, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: A multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010;11(6):521-9
36. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359(4):378-90
37. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356(2):125-34 (Pubitemid 46089673)
38. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356(2):115-24 (Pubitemid 46089672)
39. Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial. Lancet 2006;368(9544):1329- 38 (Pubitemid 44528723)
40. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356(22):2271-81 (Pubitemid 46849157)
41. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372(9637):449-56
42. Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004;4(6):423-36 (Pubitemid 38745528)
43. Chakravarthy U, Evans J, Rosenfeld PJ. Age related macular degeneration. BMJ 2010;526-30
44. Nguyen QD, Shah SM, Browning DJ, et al. A phase I study of intravitreal vascular endothelial growth factor trap-eye in patients with neovascular age-related macular degeneration. Ophthalmology 2009;116(11):2141-8 e2141
45. Ambati J, Ambati BK, Yoo SH, et al. Age-related macular degeneration: Etiology, pathogenesis, and therapeutic strategies. Surv Ophthalmol 2003;48(3):257-93 (Pubitemid 36553096)
46. Bressler SB. Introduction: Understanding the role of angiogenesis and antiangiogenic agents in age-related macular degeneration. Ophthalmology 2009;116(10 Suppl):S1-7
47. Lu M, Adamis AP. Molecular biology of choroidal neovascularization. Ophthalmol Clin North Am 2006;19(3):323-34. A detailed review on the molecular biology of choroidal neovascularization and the treatments that target this process. (Pubitemid 44403942)
48. Holder WD, Gruber HE, Roland WD, et al. Increased vascularization and heterogeneity of vascular structures occurring in polyglycolide matrices containing aortic endothelial cells implanted in the rat. Tissue Eng 1997;3(2):149-60 (Pubitemid 27271093)
49. Puolakkainen PA, Reed MJ, Gombotz WR, et al. Acceleration of wound healing in aged rats by topical application of transforming growth factor-beta(1). Wound Repair Regen 1995;3(3):330-9
50. Rivard A, Fabre JE, Silver M, et al. Age-dependent impairment of angiogenesis. Circulation 1999;99(1):111-20 (Pubitemid 29035965)
51. Sadoun E, Reed MJ. Impaired angiogenesis in aging is associated with alterations in vessel density, matrix composition, inflammatory response, and growth factor expression. J Histochem Cytochem 2003;51(9):1119-30 (Pubitemid 37059523)
52. Pacilli A, Faggioli G, Stella A, et al. An update on therapeutic angiogenesis for peripheral vascular disease. Ann Vasc Surg 2010;24(2):258-68
53. Gerber HP, Senter PD, Grewal IS. Antibody drug-conjugates targeting the tumor vasculature: Current and future developments. MAbs 2009;1(3):247-53
54. Temming K, Schiffelers RM, Molema G, et al. RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature. Drug Resist Updat 2005;8(6):381-402 (Pubitemid 43358061)
55. Murphy EA, Majeti BK, Barnes LA, et al. Nanoparticle-mediated drug delivery to tumor vasculature suppresses metastasis. Proc Natl Acad Sci USA 2008;105(27):9343-8. This article describes a method of formulating doxorubicin-loaded nanoparticles targeted to tumor vasculature via an integrin-targeting peptide, which yielded increased targeting to the site, a strong antiangiogenic effect, and, importantly, 15 times less toxicity.
56. Mitra A, Mulholland J, Nan A, et al. Targeting tumor angiogenic vasculature using polymer-RGD conjugates. J Control Release 2005;102(1):191-201 (Pubitemid 40093785)
57. Green MR, Manikhas GM, Orlov S, et al. Abraxane®, a novel Cremophor®-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. Ann Oncol 2006;17(8):1263-8 (Pubitemid 44288216)
58. Brem H, Mahaley MS, Vick NA, et al. Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas. J Neurosurg 1991;74(3):441-6
59. Perry J, Chambers A, Spithoff K, et al. Gliadel wafers in the treatment of malignant glioma: A systematic review. Curr Oncol 2007;14(5):189-94
60. Benoit DSW, Nuttelman CR, Collins SD, et al. Synthesis and characterization of a fluvastatin-releasing hydrogel delivery system to modulate hMSC differentiation and function for bone regeneration. Biomaterials 2006;27(36):6102-10 (Pubitemid 44414974)
61. Tabata Y, Miyao M, Ozeki M, et al. Controlled release of vascular endothelial growth factor by use of collagen hydrogels. J Biomater Sci Polym Ed 2000;11:915-30
62. Lutolf MP, Lauer-Fields JL, Schmoekel HG, et al. Synthetic matrix metalloproteinase-sensitive hydrogels for the conduction of tissue regeneration: Engineering cell-invasion characteristics. Proc Natl Acad Sci USA 2003;100(9):5413-18 (Pubitemid 36542719)
63. Yasuhiko T. Current status of regenerative medical therapy based on drug delivery technology. Reprod Biomed Online 2008;16(1):70-80
64. Hoare TR, Kohane DS. Hydrogels in drug delivery: Progress and challenges. Polymer 2008;49(8):1993-2007
65. Williams DF. Tissue-biomaterial interactions. J Mater Sci 1987;22(10):3421-45
66. Anderson JM, Rodriguez A, Chang DT. Foreign body reaction to biomaterials. Semin Immunol 2008;20(2):86-100
67. Willerth SM, Sakiyama-Elbert SE. Approaches to neural tissue engineering using scaffolds for drug delivery. Adv Drug Deliv Rev 2007;59(4-5):325-38 (Pubitemid 46879972)
68. Saltzman WM, Olbricht WL. Building drug delivery into tissue engineering. Nat Rev Drug Discov 2002;1(3):177-86. Although we do not delve into the technical challenges faced by tissue engineers because of ischemia, this review discusses these problems in more detail and provides examples of how drug delivery can be incorporated into several systems for improved neovasculature or tissue growth. (Pubitemid 37361421)
69. Schakenraad JM, Hardonk MJ, Feijen J, et al. Enzymatic activity toward poly(L-lactic acid) implants. J Biomed Mater Res 1990;24(5):529-45 (Pubitemid 20269701)
70. Spenlehauer G, Vert M, Benoit JP, et al. In vitro and in vivo degradation of poly(D,L lactide/glycolide) type microspheres made by solvent evaporation method. Biomaterials 1989;10(8):557-63
71. Anderson JM, Shive MS. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Deliv Rev 1997;28(1):5-24 (Pubitemid 27497671)
72. Panyam J, Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev 2003;55(3):329-47 (Pubitemid 36297053)
73. Faraji AH, Wipf P. Nanoparticles in cellular drug delivery. Bioorg Med Chem 2009;17(8):2950-62
74. Freiberg S, Zhu XX. Polymer microspheres for controlled drug release. Int J Pharm 2004;282(1-2):1-18 (Pubitemid 39178480)
75. Varde NK, Pack DW. Microspheres for controlled release drug delivery. Expert Opin Biol Ther 2004;4(1):35-51 (Pubitemid 38057265)
76. Patil SD, Papadmitrakopoulos F, Burgess DJ. Concurrent delivery of dexamethasone and VEGF for localized inflammation control and angiogenesis. J Control Release 2007;117(1):68-79 (Pubitemid 46164863)
77. Visscher GE, Pearson JE, Fong JW, et al. Effect of particle size on the in vitro and in vivo degradation rates of poly(DL-lactide-co-glycolide) microcapsules. J Biomed Mater Res 1988;22(8):733-46
78. Grizzi I, Garreau H, Li S, et al. Hydrolytic degradation of devices based on poly(-lactic acid) size-dependence. Biomaterials 1995;16(4):305-11
79. Bertram JP, Jay SM, Hynes SR, et al. Functionalized poly(lactic- coglycolic acid) enhances drug delivery and provides chemical moieties for surface engineering while preserving biocompatibility. Acta Biomater 2009;5(8):2860-71
80. Blanco MD, Alonso MJ. Development and characterization of protein-loaded poly(lactide-co-glycolide) nanospheres. Eur J Pharm Biopharm 1997;43(3):287-94
81. Qi H, Hu P, Xu J, et al. Encapsulation of drug reservoirs in fibers by emulsion electrospinning: Morphology characterization and preliminary release assessment. Biomacromolecules 2006;7(8):2327-30 (Pubitemid 44336343)
82. Holland TA, Tabata Y, Mikos AG. In vitro release of transforming growth factor-[beta]1 from gelatin microparticles encapsulated in biodegradable, injectable oligo(poly(ethylene glycol) fumarate) hydrogels. J Control Release 2003;91(3):299-313 (Pubitemid 36976762)
83. Tzeng SY, Lavik EB. Photopolymerizable nanoarray hydrogels deliver CNTF and promote differentiation of neural stem cells. Soft Matter 2010;6(10):2208-15
84. Dobrovolskaia MA, Aggarwal P, Hall JB, et al. Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution. Mol Pharm 2008;5(4):487-95
85. Li S-D, Huang L. Pharmacokinetics and biodistribution of nanoparticles. Mol Pharm 2008;5(4):496-504
86. Owens Iii DE, Peppas NA. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm 2006;307(1):93-102 (Pubitemid 41773257)
87. Bertram JP, Williams CA, Robinson R, et al. Intravenous hemostat: Nanotechnology to halt bleeding. Sci Transl Med 2009;1(11):11ra22
88. Shmueli RB, Anderson DG, Green JJ. Electrostatic surface modifications to improve gene delivery. Expert Opin Drug Deliv 2010;7(4):535-50
89. Jones M, Leroux J. Polymeric micelles - a new generation of colloidal drug carriers. Eur J Pharm Biopharm 1999;48(2):101-11 (Pubitemid 29401986)
90. Gulati M, Grover M, Singh S, et al. Lipophilic drug derivatives in liposomes. Int J Pharm 1998;165(2):129-68 (Pubitemid 28239702)
91. Fresta M, Puglisi G, Panico AM, et al. Cdp-Choline entrapment and release from multilamellar and reverse-phase evaporation liposomes. Drug Dev Ind Pharm 1993;19(5):559-85 (Pubitemid 23063387)
92. Vadiei K, Lopez-Berestein G, Perez-Soler R, et al. In vitro evaluation of liposomal cyclosporine. Int J Pharm 1989;57(2):133-8 (Pubitemid 20011836)
93. Damen J, Regts J, Scherphof G. Transfer and exchange of phospholipid between small unilamellar liposomes and rat plasma high density lipoproteins. Dependence on cholesterol content and phospholipid composition. Biochim Biophys Acta 1981;665(3):538-45 (Pubitemid 11011393)
94. Chonn A, Semple SC, Cullis PR. Association of blood proteins with large unilamellar liposomes in vivo. Relation to circulation lifetimes. J Biol Chem 1992;267(26):18759-65
95. Senior J, Gregoriadis G. Is half-life of circulating liposomes determined by changes in their permeability? FEBS Lett 1982;145(1):109-14 (Pubitemid 12002281)
96. Juliano RL, Stamp D. The effect of particle size and charge on the clearance rates of liposomes and liposome encapsulated drugs. Biochem Biophys Res Commun 1975;63(3):651-8
97. Scherphof GL, Dijkstra J, Spanjer HH, et al. Uptake and intracellular processing of targeted and nontargeted liposomes by rat Kupffer cells in vivo and in vitro. Ann NY Acad Sci 1985;446:368-84 (Pubitemid 16238580)
98. Alving CR, Steck EA, Chapman WL Jr, et al. Therapy of leishmaniasis: Superior efficacies of liposome-encapsulated drugs. Proc Natl Acad Sci USA 1978;75(6):2959-63 (Pubitemid 8378744)
99. Harashima H, Sakata K, Funato K, et al. Enhanced hepatic uptake of liposomes through complement activation depending on the size of liposomes. Pharm Res 1994;11(3):402-6 (Pubitemid 24117360)
100. Senior JH. Fate and behavior of liposomes in vivo: A review of controlling factors. Crit Rev Ther Drug Carrier Syst 1987;3(2):123-93 (Pubitemid 17219201)
101. Soppimath KS, Aminabhavi TM, Kulkarni AR, et al. Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release 2001;70(1-2):1-20 (Pubitemid 32144788)
102. Discher DE, Ahmed F. Polymersomes. Annu Rev Biomed Eng 2006;8:323-41 (Pubitemid 44314820)
103. Letchford K, Burt H. A review of the formation and classification of amphiphilic block copolymer nanoparticulate structures: Micelles, nanospheres, nanocapsules and polymersomes. Eur J Pharm Biopharm 2007;65(3):259-69 (Pubitemid 46321600)
104. Luo LB, Eisenberg A. Thermodynamic size control of block copolymer vesicles in solution. Langmuir 2001;17(22):6804-11 (Pubitemid 35330561)
105. Fischer D, Bieber T, Li Y, et al. A novel non-viral vector for DNA delivery based on low molecular weight, branched polyethylenimine: Effect of molecular weight on transfection efficiency and cytotoxicity. Pharm Res 1999;16(8):1273-9 (Pubitemid 29393618)
106. Putnam D. Polymers for gene delivery across length scales. Nat Mater 2006;5(6):439-51. This review identifies many of the advantages and challenges associated with gene delivery in a wide range of systems. (Pubitemid 43838906)
107. Leong KW, Mao HQ, Truong-Le VL, et al. DNA-polycation nanospheres as non-viral gene delivery vehicles. J Control Release 1998;53(1-3):183-93 (Pubitemid 28218701)
108. Haensler J, Szoka FC. Polyamidoamine cascade polymers mediate efficient transfection of cells in culture. Bioconjug Chem 1993;4(5):372-9
109. Green JJ, Langer R, Anderson DG. A combinatorial polymer library approach yields insight into nonviral gene delivery. Acc Chem Res 2008;41(6):749-59
110. Bhise NS, Gray RS, Sunshine JC, et al. The relationship between terminal functionalization and molecular weight of a gene delivery polymer and transfection efficacy in mammary epithelial 2-D cultures and 3-D organotypic cultures. Biomaterials 2010;31(31):8088-96
111. Thomas CE, Ehrhardt A, Kay MA. Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet 2003;4(5):346-58 (Pubitemid 36538359)
112. Green JJ, Shi J, Chiu E, et al. Biodegradable polymeric vectors for gene delivery to human endothelial cells. Bioconjug Chem 2006;17:1162-9 (Pubitemid 44455324)
113. Green JJ, Zugates GT, Tedford NC, et al. Combinatorial modification of degradable polymers enables transfection of human cells comparable to adenovirus. Adv Mater 2007;19(19):2836-42 (Pubitemid 47597872)
114. Sunshine J, Green JJ, Mahon K, et al. Small molecule end group of linear polymer determine cell-type gene delivery efficacy. Adv Mater 2009;21(48):4947-51
115. Yang F, Cho SW, Son SM, et al. Genetic engineering of human stem cells for enhanced angiogenesis using biodegradable polymeric nanoparticles. Proc Natl Acad Sci USA 2009;107(8):3317-22
116. Karoubi G, Ormiston ML, Stewart DJ, et al. Single-cell hydrogel encapsulation for enhanced survival of human marrow stromal cells. Biomaterials 2009;30(29):5445-55
117. Orive G, De Castro M, Kong H-J, et al. Bioactive cell-hydrogel microcapsules for cell-based drug delivery. J Control Release 2009;135(3):203-10
118. Roger M, Clavreul A, Venier-Julienne M-C, et al. Mesenchymal stem cells as cellular vehicles for delivery of nanoparticles to brain tumors. Biomaterials 2010;31(32):8393-401
119. Devika BC, Michael D, James S, et al. Cellular uptake and transport of gold nanoparticles incorporated in a liposomal carrier. Nanomedicine 2010;6(1):161-9
120. Hernández RM, Orive G, Murua A, et al. Microcapsules and microcarriers for in situ cell delivery. Adv Drug Deliv Rev 2010;62(7-8):711-30
121. Soker S, Machado M, Atala A. Systems for therapeutic angiogenesis in tissue engineering. World J Urol 2000;18(1):10-18
122. Han Bae Y, Mikos AG. Cells for drug delivery platforms. Adv Drug Deliv Rev 2000;42(1-2):1-2 (Pubitemid 30609632)
123. Tresco PA, Biran R, Noble MD. Cellular transplants as sources for therapeutic agents. Adv Drug Deliv Rev 2000;42(1-2):3-27 (Pubitemid 30609633)
124. Sheyn D, Mizrahi O, Benjamin S, et al. Genetically modified cells in regenerative medicine and tissue engineering. Adv Drug Deliv Rev 2010;62(7-8):683-98
125. Lu J, Liong M, Zink JI, et al. Mesoporous silica nanoparticles as a delivery system for hydrophobic anticancer drugs. Small 2007;3(8):1341-6 (Pubitemid 47245524)
126. Salonen J, Kaukonen AM, Hirvonen J, et al. Mesoporous silicon in drug delivery applications. J Pharm Sci 2008;97(2):632-53 (Pubitemid 351293873)
127. Tanaka T, Mangala LS, Vivas-Mejia PE, et al. Sustained small interfering RNA delivery by mesoporous silicon particles. Cancer Res 2010;70(9):3687-96
128. Weissleder R, Elizondo G, Wittenberg J, et al. Ultrasmall superparamagnetic iron oxide: Characterization of a new class of contrast agents for MR imaging. Radiology 1990;175(2):489-93 (Pubitemid 20135290)
129. Lee H, Lee E, Kim DK, et al. Antibiofouling polymer-coated superparamagnetic iron oxide nanoparticles as potential magnetic resonance contrast agents for in vivo cancer imaging. J Am Chem Soc 2006;128(22):7383-9 (Pubitemid 43849141)
130. De Cuyper M, Joniau M. Magnetoliposomes. Formation and structural characterization. Eur Biophys J 1988;15(5):311-19 (Pubitemid 18058038)
131. Zhang C, Jugold M, Woenne EC, et al. Specific targeting of tumor angiogenesis by RGD-conjugated ultrasmall superparamagnetic iron oxide particles using a clinical 1.5-T magnetic resonance scanner. Cancer Res 2007;67(4):1555-62 (Pubitemid 46383379)
132. Kawano T, Yamagata M, Takahashi H, et al. Stabilizing of plasmid DNA in vivo by PEG-modified cationic gold nanoparticles and the gene expression assisted with electrical pulses. J Control Release 2006;111(3):382-9
133. Lee J-S, Green JJ, Love KT, et al. Gold, Poly(B-amino ester) nanoparticles for small interfering RNA delivery. Nano Lett 2009;9(6):2402-6
134. Hirsch LR, Stafford RJ, Bankson JA, et al. Nanoshell-mediated near-infrared thermal therapy of tumors under magnetic resonance guidance. Proc Natl Acad Sci USA 2003;100(23):13549-54 (Pubitemid 37444779)
135. Nel A, Xia T, Madler L, et al. Toxic potential of materials at the nanolevel. Science 2006;311(5761):622-7. Given the potential advantages of using nano-sized carriers for antitumor drug delivery, it is important to understand size-dependent changes in properties. Whereas many biocompatibility studies are done with larger materials, this article examines the biological effects of objects specifically within this size range. (Pubitemid 43191298)
136. Di Pasqua AJ, Sharma KK, Shi Y-L, et al. Cytotoxicity of mesoporous silica nanomaterials. J Inorg Biochem 2008;102(7):1416-23
137. Folkman J. Angiogenesis. Annu Rev Med 2006;57:1-18 (Pubitemid 43261975)
138. Ebos JML, Lee CR, Christensen JG, et al. Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. Proc Natl Acad Sci USA 2007;104(43):17069-74 (Pubitemid 350210993)
139. Ebos JML, Lee CR, Cruz-Munoz W, et al. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009;15(3):232-9
140. Fischer C, Jonckx B, Mazzone M, et al. Anti-PlGF inhibits growth of VEGF(R)- inhibitor-resistant tumors without affecting healthy vessels. Cell 2007;131(3):463-75. This article describes the benefits of using a combination of antiangiogenic drugs for increased tumor-killing efficacy and reduced toxicity, branching outside the anti-VEGF therapies that are more often studied. (Pubitemid 350007692)
141. Mac Gabhann F, Qutub AA, Annex BH, et al. Systems biology of pro-angiogenic therapies targeting the VEGF system. Rev Syst Biol Med 2010;2(6):694-707
142. Tang C, Russell PJ, Martiniello-Wilks R, et al. Concise review: Nanoparticles and cellular carriers-allies in cancer imaging and cellular gene therapy? Stem Cells 2010;28(9):1686-702
143. Phillips MA, Gran ML, Peppas NA. Targeted nanodelivery of drugs and diagnostics. Nano Today 2010;5(2):143-59
144. Greish K. Enhanced permeability and retention of macromolecular drugs in solid tumors: A royal gate for targeted anticancer nanomedicines. J Drug Target 2007;15(7-8):457-64 (Pubitemid 47209047)
145. Sipkins DA, Cheresh DA, Kazemi MR, et al. Detection of tumor angiogenesis in vivo by [alpha]v[beta]3-targeted magnetic resonance imaging. Nat Med 1998;4(5):623-6 (Pubitemid 28237365)
146. Li L, Wartchow CA, Danthi SN, et al. A novel antiangiogenesis therapy using an integrin antagonist or anti-Flk-1 antibody coated 90Y-labeled nanoparticles. Int J Radiat Oncol Biol Phys 2004;58(4):1215-27 (Pubitemid 38314807)
147. Dellian M, Yuan F, Trubetskoy VS, et al. Vascular permeability in a human tumour xenograft: Molecular charge dependence. Br J Cancer 2000;82(9):1513-8 (Pubitemid 30204355)
148. Juliano RL, Stamp D. The effect of particle size and charge on the clearance rates of liposomes and liposome encapsulated drugs. Biochem Biophys Res Commun 1975;63(3):651-8
149. Abu-Lila A, Suzuki T, Doi Y, et al. Oxaliplatin targeting to angiogenic vessels by PEGylated cationic liposomes suppresses the angiogenesis in a dorsal air sac mouse model. J Control Release 2009;134(1):18-25
150. Kunstfeld R, Wickenhauser G, Michaelis U, et al. Paclitaxel encapsulated in cationic liposomes diminishes tumor angiogenesis and melanoma growth in a 'humanized' SCID mouse model. J Investig Dermatol 2003;120(3):476-82 (Pubitemid 36298435)
151. Brown EB, Campbell RB, Tsuzuki Y, et al. In vivo measurement of gene expression, angiogenesis and physiological function in tumors using multiphoton laser scanning microscopy. Nat Med 2001;7(7):864-8 (Pubitemid 32691644)
152. Jain RK. Transport of molecules, particles, and cells in solid tumors. Annu Rev Biomed Eng 1999;1:241-63 (Pubitemid 129740012)
153. Endrich B, Reinhold HS, Gross JF, et al. Tissue perfusion inhomogeneity during early tumor growth in rats. J Natl Cancer Inst 1979;62(2):387-95 (Pubitemid 9094732)
154. Teesalu T, Sugahara KN, Kotamraju VR, et al. C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration. Proc Natl Acad Sci USA 2009;106(38):16157-62
155. Porkka K, Laakkonen P, Hoffman JA, et al. A fragment of the HMGN2 protein homes to the nuclei of tumor cells and tumor endothelial cells in vivo. Proc Natl Acad Sci USA 2002;99(11):7444-9 (Pubitemid 34568710)
156. Nanda A, Carson-Walter EB, Seaman S, et al. TEM8 interacts with the cleaved C5 domain of collagen alpha 3(VI). Cancer Res 2004;64(3):817-20 (Pubitemid 38176877)
157. Carson-Walter EB, Watkins DN, Nanda A, et al. Cell surface tumor endothelial markers are conserved in mice and humans. Cancer Res 2001;61(18):6649-55 (Pubitemid 32896479)
158. Pasut G, Veronese FM. PEG conjugates in clinical development or use as anticancer agents: An overview. Adv Drug Deliv Rev 2009;61(13):1177-88
159. Mordenti J, Cuthbertson RA, Ferrara N, et al. Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration. Toxicol Pathol 1999;27(5):536-44 (Pubitemid 29446822)
160. Schmucker C, Ehlken C, Hansen LL, et al. Intravitreal bevacizumab (Avastin) vs. ranibizumab (Lucentis) for the treatment of age-related macular degeneration: A systematic review. Curr Opin Ophthalmol 2010;21(3):218-26
161. Subramanian ML, Abedi G, Ness S, et al. Bevacizumab vs ranibizumab for age-related macular degeneration: 1-year outcomes of a prospective, double-masked randomised clinical trial. Eye (Lond) 2010;24(11):1708-15. A very recent study on the comparative effects of bevacizumab and ranibizumab.
162. Holash J, Davis S, Papadopoulos N, et al. VEGF-Trap: A VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 2002;99(17):11393-8 (Pubitemid 34920936)
163. Del Amo EM, Urtti A. Current and future ophthalmic drug delivery systems. A shift to the posterior segment. Drug Discov Today 2008;13(3-4):135-43. A
164. Kim SH, Lutz RJ, Wang NS, et al. Transport barriers in transscleral drug delivery for retinal diseases. Ophthalmic Res 2007;39(5):244-54 (Pubitemid 47557244)
165. Gaudana R, Ananthula HK, Parenky A, et al. Ocular drug delivery. AAPS J 2010;12(3):348-60
166. Kawashima T, Nagai N, Kaji H, et al. A scalable controlled-release device for transscleral drug delivery to the retina. Biomaterials 2010;32(7):1950-6. The article describes work on a transscleral drug delivery platform that can deliver a range of therapeutics to the posterior segment of the eye. The authors describe the release kinetics and tissue penetration of the drug into the retinal tissue.
167. Kim H, Csaky KG. Nanoparticle-integrin antagonist C16Y peptide treatment of choroidal neovascularization in rats. J Control Release 2010;142(2):286-93
168. Karagiannis ED, Popel AS. A systematic methodology for proteome-wide identification of peptides inhibiting the proliferation and migration of endothelial cells. Proc Natl Acad Sci USA 2008;105(37):13775-80
169. Koskimaki JE, Karagiannis ED, Rosca EV, et al. Peptides derived from type IV collagen, CXC chemokines, and thrombospondin-1 domain-containing proteins inhibit neovascularization and suppress tumor growth in MDA-MB-231 breast cancer xenografts. Neoplasia 2009;11(12):1285-91
170. Molokhia SA, Sant H, Simonis J, et al. The capsule drug device: Novel approach for drug delivery to the eye. Vision Res 2010;50(7):680-5. The authors describe a drug delivery device that can be implanted into the eye during cataract surgery. The device can deliver the drug in a controlled fashion and the reservoir can be refilled without removing the implant.
171. Campochiaro PA, Hafiz G, Shah SM, et al. Sustained ocular delivery of fluocinolone acetonide by an intravitreal insert. Ophthalmology 2010;117(7):1393-99 e1393
172. Yasukawa T, Ogura Y. Medical devices for the treatment of eye diseases. Handb Exp Pharmacol 2010;197:469-89
173. Campbell M, Nguyen AT, Kiang AS, et al. An experimental platform for systemic drug delivery to the retina. Proc Natl Acad Sci USA 2009;106(42):17817-22
174. Losordo DW, Dimmeler S. Therapeutic angiogenesis and vasculogenesis for ischemic disease: Part II: Cell-based therapies. Circulation 2004;109(22):2692-7 (Pubitemid 38737912)
175. Losordo DW, Dimmeler S. Therapeutic angiogenesis and vasculogenesis for ischemic disease. Part I: Angiogenic cytokines. Circulation 2004;109(21):2487-91 (Pubitemid 38720544)
176. Gupta R, Tongers J, Losordo DW. Human studies of angiogenic gene therapy. Circ Res 2009;105(8):724-36. This article reviews the development of clinical trials of therapeutic angiogenesis and evaluates their outcomes. Based on this analysis of past clinical data, the authors highlight future directions that can help guide preclinical studies and clinical trials of proangiogenic gene therapies.
177. Christensen LV, Chang CW, Yockman JW, et al. Reducible poly (amido ethylenediamine) for hypoxia-inducible VEGF delivery. J Control Release 2007;118(2):254-61. This article presents a good example of using a biodegradable polymer-based non-viral approach to deliver growth factors to induce therapeutic angiogenesis in ischemic tissues. A physiologically reducible disulfide poly(amido ethylenediamine) (SS-PAED) was used as a carrier for VEGF plasmid delivery for myocardial ischemia therapy in vitro as well as in a rabbit model. (Pubitemid 46329738)
178. Isner JM, Pieczek A, Schainfeld R, et al. Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb. Lancet 1996;348(9024):370-4 (Pubitemid 26261511)
179. Shyu KG, Chang H, Wang BW, et al. Intramuscular vascular endothelial growth factor gene therapy in patients with chronic critical leg ischemia. Am J Med 2003;114(2):85-92 (Pubitemid 36183588)
180. Rajagopalan S, Mohler ER III, Lederman RJ, et al. Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: A phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation 2003;108(16):1933-8 (Pubitemid 37296537)
181. Golub JS, Kim YT, Duvall CL, et al. Sustained VEGF delivery via PLGA nanoparticles promotes vascular growth. Am J Physiol Heart Circ Physiol 2010;298(6):H1959-65
182. Rey S, Lee K, Wang CJ, et al. Synergistic effect of HIF-1alpha gene therapy and HIF-1-activated bone marrow-derived angiogenic cells in a mouse model of limb ischemia. Proc Natl Acad Sci USA 2009;106(48):20399-404. This article describes an example of the recent combinatorial approaches pursued to improve the therapeutic proangiogenesis response in peripheral vascular disease models. In this study, the authors investigated the synergistic effect of delivering bone marrow-derived angiogenic cells and adenoviruses expressing HIF-1alpha in a mouse limb ischemia model. The cells were primed to express integrins to enhance ischemic tissue targeting.
183. Tabata II. The importance of drug delivery systems in tissue engineering. Pharm Sci Technol Today 2000;3(3):80-9
184. Rodriguez A, Cao YL, Ibarra C, et al. Characteristics of cartilage engineered from human pediatric auricular cartilage. Plast Reconstr Surg 1999;103(4):1111-19 (Pubitemid 29135569)
185. Saim AB, Cao YL, Weng YL, et al. Engineering autogenous cartilage in the shape of a helix using an injectable hydrogel scaffold. Laryngoscope 2000;110(10):1694-7
186. Lavik E, Langer R. Tissue engineering: Current state and perspectives. Appl Microbiol Biotechnol 2004;65(1):1-8 (Pubitemid 39044304)
187. Vinatier C, Mrugala D, Jorgensen C, et al. Cartilage engineering: A crucial combination of cells, biomaterials and biofactors. Trends Biotechnol 2009;27(5):307-14
188. Domm C, Schunke M, Christesen K, et al. Redifferentiation of dedifferentiated bovine articular chondrocytes in alginate culture under low oxygen tension. Osteoarthritis Cartilage 2002;10(1):13-22 (Pubitemid 34120986)
189. Guillemin K, Krasnow MA. The hypoxic response: Huffing and HIFing. Cell 1997;89(1):9-12 (Pubitemid 27180579)
190. Schipani E, Ryan HE, Didrickson S, et al. Hypoxia in cartilage: HIF-1alpha is essential for chondrocyte growth arrest and survival. Genes Dev 2001;15(21):2865-76 (Pubitemid 33042056)
191. Hunziker EB. Articular cartilage repair: Problems and perspectives. Biorheology 2000;37(1-2):163-4 (Pubitemid 30353545)
192. Raghunath J, Rollo J, Sales KM, et al. Biomaterials and scaffold design: Key to tissue-engineering cartilage. Biotechnol Appl Biochem 2007;46(Pt 2):73-84
193. Losi P, Briganti E, Magera A, et al. Tissue response to poly(ether)urethanepolydimethylsiloxane- fibrin composite scaffolds for controlled delivery of pro-angiogenic growth factors. Biomaterials 2010;31(20):5336-44. This article emphasizes the importance of developing biocompatible delivery systems that enable localized and controlled release of multiple angiogenic growth factors to enhance the therapeutic angiogenesis response during tissue regeneration.
194. Papanas N, Maltezos E. Benefit-risk assessment of becaplermin in the treatment of diabetic foot ulcers. Drug Saf 2010;33(6):455-61
195. Leitner GC, Gruber R, Neumuller J, et al. Platelet content and growth factor release in platelet-rich plasma: A comparison of four different systems. Vox Sang 2006;91(2):135-9 (Pubitemid 44126609)
196. Kita Y, Nogimura H, Ida M, et al. Time course of gene expression after the injection of adenoviral vectors containing CTLA4IG gene. Transplant Proc 2004;36(8):2443-5 (Pubitemid 39550869)
197. Leong-Poi H, Kuliszewski MA, Lekas M, et al. Therapeutic arteriogenesis by ultrasound-mediated VEGF165 plasmid gene delivery to chronically ischemic skeletal muscle. Circ Res 2007;101(3):295-303 (Pubitemid 47344079)
198. Rasmussen H, Chu KW, Campochiaro P, et al. Clinical protocol. An open-label, phase I, single administration, dose-escalation study of ADGVPEDF.11D (ADPEDF) in neovascular age-related macular degeneration (AMD). Hum Gene Ther 2001;12(16):2029-32
199. Dechantsreiter MA, Planker E, Matha B, et al. N-Methylated Cyclic RGD peptides as highly active and selective alpha-v-beta-3 integrin antagonists. J Med Chem 1999;42(16):3033-40 (Pubitemid 29384038)
200. Reddy KR, Wright TL, Pockros PJ, et al. Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C. Hepatology 2001;33(2):433-8 (Pubitemid 32119033)
201. Bukowski RM, Tendler C, Cutler D, et al. Treating cancer with PEG Intron: Pharmacokinetic profile and dosing guidelines for an improved interferon-alpha-2b formulation. Cancer 2002;95(2):389-96 (Pubitemid 34787605)
202. Lindsay KL, Trepo C, Heintges T, et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001;34(2):395-403 (Pubitemid 32702353)